Compare AbCellera Biologics Inc (ABCL) vs Vanguard Total Bond Market Index Fund ETF (BND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Vanguard Total Bond Market Index Fund ETF — how do they compare? AbCellera Biologics Inc trades at $10.33 (market cap $2.99B), while Vanguard Total Bond Market Index Fund ETF trades at $72.29. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, Vanguard Total Bond Market Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | BND | |
|---|---|---|
Market Cap | $2.99B | — |
Sector | Health | — |
52-Week High | $10.36 | $75.17 |
52-Week Low | $2.78 | $72.15 |
Enterprise Value | $2.58B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $10.34, up 10.71% on positive Phase 2 trial results for its menopause drug ABCL635, which showed 83% reduction in hot flashes. Despite negative profitability metrics, the stock maintains strong analyst support with 91.7% buy ratings and a $15.50 consensus target. Technical indicators show bullish momentum with the price near resistance at $11, though RSI levels suggest overbought conditions.
The outlook remains speculative given ongoing losses but is supported by promising clinical data and strategic partnerships. Key risks include drug development timelines, cash burn, and reliance on successful commercialization. Upside potential exists if ABCL635 advances successfully through regulatory phases.
BND trades at $72.28, up 0.18% on the day, with a bearish technical signal driven by moving averages. Recent corporate actions include dividend payments of $0.25-$0.24, with the next scheduled for August 5, 2026. The ETF's neutral oscillators and flat support/resistance at $72 suggest consolidation. News highlights focus on bond ETF inflows and institutional positioning shifts.
The outlook remains cautious amid rising Treasury yields and inflation concerns. Opportunities lie in BND's role as a core fixed-income holding for diversification, but risks include interest rate sensitivity and macroeconomic volatility. Investor sentiment is mixed, balancing yield appeal against bond market headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Vanguard Total Bond Market Index Fund ETF
This index measures the performance of a wide spectrum of public, investment-grade, taxable, fixed income securities in the US, including government, corporate, and international dollar-denominated bonds, as well as mortgage-backed and asset-backed securities-all with maturities of more than 1 year. All of the fund's investments will be selected through the sampling process, and at least 80% of its assets will be invested in bonds held in the index.
Read more on BND →
